<DOC>
	<DOCNO>NCT03008083</DOCNO>
	<brief_summary>This study prospective , multi-center , open-label , randomize control clinical trial , aim assess clinical noninferiority 3 month ( short-term ) v 12 month ( long-term ) Dual Anti-Platelet Therapy ( DAPT ) patient undergo percutaneous coronary intervention implant sirolimus target- elute stent abluminal groove contain biodegradable polymer ( Firehawk™ stent ) . All participant meet inclusion criterion begin take aspirin open-label thienopyridine therapy index procedure , 1:1 randomize 3 month 12 month DAPT index procedure .</brief_summary>
	<brief_title>Comparison Three v Twelve Months Dual Anti-Platelet Therapy After Stent Implantation</brief_title>
	<detailed_description>This study recruit 2,446 subject stable coronary artery disease 40 research center China . All participant meet inclusion criterion 1:1 randomize 3 month 12 month DAPT implant Firehawk™ coronary stent.Clinical follow-up carry 30 day , 3 month , 6 month , 12 month , 18 month , 2 year 3 year index procedure.The primary study endpoint Net Adverse Clinical Cerebral Events ( NACCE ) , composite all-cause death , myocardial infarction ( MI ) , cerebral vascular accident ( CVA ) major bleeding ( academic research consortium [ ARC ] definition GUSTO definition ) 18 month . Subjects complete 18 month follow-up regard complete primary endpoint . The secondary study endpoint contain ARC define stent thrombosis ( ST ) study time-points ; NACCE 30 days,6,12,24 36 month follow-up ; major adverse cardiovascular event ( MACE ) , major adverse cardiovascular cerebral event ( MACCE ) , target lesion revascularization ( TLR ) , target lesion failure ( TLF ) , ST 30 days,6,12 ,18,24 36 month follow-up ; major bleed 1 , 3 , 6 , 12 ,18,24 36 month follow ; well cost-effective 18 month follow-up .</detailed_description>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>General Age ≥ 18 year ; Subjects ( legal guardian ) understand test requirement procedure , provide write informed consent ; Subjects could undergo percutaneous coronary intervention ( PCI ) ; Subjects symptomatic coronary artery disease confirm asymptomatic ischemia ; Subjects eligible candidate coronary artery bypass graft surgery ( CABG ) ; Left ventricular ejection fraction ( LVEF ) within 60 day ≥ 30 % ; Subjects willing accept trial plan call subsequent evaluation . Angiographic Target lesion must new visually estimate reference diameter ≥2.25 mm ≤4.0 mm autologous coronary artery ; No limitation target lesion length number ; The first target lesion must able successfully expand implant Firehawk™ stent . Clinical Subjects recently suffer MI ( within 1 week ) , ECG changes/clinical symptom consistent AMI accompany increased cardiac biomarkers ( CKMB , CK , TNT TNI ) exclude : Subjects organ transplant wait organ transplant ; Subjects receive chemotherapy receive chemotherapy within 30 day PCI ; Subjects undergoing chronic ( 72 hour ) anticoagulant therapy ( heparin coumarin ) acute coronary syndrome ; Subjects abnormal count platelet white blood cell ( WBC ) : platelet count less 100×10E9/L great 700×10E9/L , white blood cell less 3×10E9/L ; Subjects confirm suspect liver disease , include hepatitis lab result ; Subjects elevate serum creatinine level &gt; 3.0mg/dL undergoing dialysis therapy ; Subjects active peptic ulcer , active gastrointestinal ( GI ) bleed bleed diathesis coagulopathy , refuse blood transfusion ; Subjects cerebral vascular accident ( CVA ) transient ischemic attack ( TIA ) past 6 month , permanent nerve defect ; Subjects PCI ( balloon angioplasty , stent , cut balloon , atherectomy ) treatment target vessel ( include collateral ) within 12 month prior baseline ; Subjects plan undergo PCI CABG within 18 month baseline PCI ; Subjects coronary endovascular brachytherapy treatment previously ; Subjects associate drug allergy ( sirolimus , structurerelated compound fluorinated polymer , thiophenepyridine aspirin ) ; Subjects suffer serious illness ( cancer , congestive heart failure ) , may cause drop life expectancy le 18 month ; Subjects currently abuse drug ( alcohol , cocaine , heroin , etc ) ; Subject plan undergo operation may lead confuse programme ; Subjects participate another study drug medical device meet primary endpoint ; Subjects plan pregnant within 18 month baseline ; Subjects pregnant breastfeed woman . Angiographic Target lesion follow criterion : left main , saphenous vein graft arterial graft , via saphenous vein graft arterial graft , instent sestenosis ; Subjects unprotected leave main coronary artery disease ( diameter stenosis &gt; 50 % ) ; Subjects protect leave main coronary artery disease ( diameter stenosis &gt; 50 % leave coronary artery bypass surgery ) , well target lesion locate LAD LCX ; Subjects lesions clinical significance , may need intervention within 18 month baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>